Trump should be good medicine for the pharmaceutical industry. Here’s why
Stat - 11/15/2016
For a president with a populist base — and a seemingly populist streak — the public anger may be hard to ignore. Moreover, Trump can be a wild card. He did sound off, albeit briefly, about prescription drug prices during the campaign. And he’s yet to issue any policy proposals.
“He’s against price controls and surrounded himself with pro-industry advisers, but he may not be against allowing Medicare to negotiate,” said Brook Baker, a professor at Northeastern University School of Law and a senior policy analyst for Health GAP, a group that advocates for wider access to medicines. “But it’s hard to know. He may not do anything.”